Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

AbbVie’s Parkinson’s disease therapy application rejected by FDA

The regulator has requested more information on the pump used to administer ABBV-95

- PMLiVE

Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance affects around 15.5% to 46.5% of the world’s population

- PMLiVE

The increasing value of rare disease trials

By Emily Wigginton

- PMLiVE

Wrapping up EAU with a Look at Medscape’s Urology Impact

The Medscape Education Global team has returned from EAU in Milan, Italy, having presented an educational symposium and a networking event with Urology faculty and supporters.The educational symposium, Harnessing the...

Medscape Education

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children

Dupixent is now the first and only targeted medicine in the EU for this patient population

- PMLiVE

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

If approved, the test could streamline the journey to diagnosis for more patients

- PMLiVE

Inizio appoints Stefanie Christmas as global head of DE&I

Christmas joins from Vynamic, where she founded the firm’s DE&I efforts in 2016

- PMLiVE

Rare diseases: not so rare after all

The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis

Atopic dermatitis affects over 26 million people in the US alone

- PMLiVE

Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis

Plaque psoriasis accounts for around 80-90% of the 125 million psoriasis cases worldwide

- PMLiVE

UCB’s bimekizumab shows continued improvement in hidradenitis suppurativa patients

There is currently only one approved biologic treatment for the inflammatory skin disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links